Few would think professional sports leagues and the drug-development industry have much in common. When it comes to building ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other pharma stocks. Healthcare takes the concept of ‘defensive’ further than almost any ...

At a public forum last week, Peter Marks, the top vaccine regulator for the Food and Drug Administration, said the way to counter the movement is by being transparent. “We have to be steadfast ...

Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...

AbbVie announced Monday that it is buying Aliada Therapeutics, along with its lead drug candidate ALIA-1758 — an experimental antibody being tested for treating Alzheimer’s disease ...

Patient advocates are hoping for change under new director Michelle Tarver, while industry groups look to build on former ...

The AbbVie Foundation, a nonprofit dedicated to addressing health inequities, has made a $75 million donation to the University of Chicago to support the construction of UChicago Medicine’s new cancer ...

AbbVie is entering into a collaboration and option-to-license deal with EvolveImmune Therapeutics to develop biologics for multiple oncology targets. Connecticut-based EvolveImmune, which develops ...

AbbVie’s deal team is having a busy week. Days after inking a $1.4 billion buyout, the drugmaker has put up the same again in biobucks to secure options on multispecific T-cell engagers from ...

(RTTNews) - AbbVie (ABBV) and EvolveImmune Therapeutics announced a collaboration and option-to-license agreement to develop multispecific biologics for multiple targets in oncology. The ...